Company profile: NanoVibronix
1.1 - Company Overview
Company description
- Provider of portable therapeutic ultrasound medical devices, including PainShield, a wearable device delivering localized energy to relieve pain and promote soft tissue healing; UroShield, a urology device that creates an acoustic shield on urinary catheters to prevent bacterial biofilm, reduce infections, and alleviate catheter-related pain and discomfort; and WoundShield, a patch-based device that promotes wound healing.
Products and services
- WoundShield: A patch-based device utilizing low-frequency, low-intensity ultrasound to promote wound healing by increasing blood supply and oxygen to the affected area
- UroShield: An ultrasonic urology therapy device that creates an acoustic shield on urinary catheters, preventing bacterial biofilm formation, reducing infections, and alleviating catheter-related pain and discomfort
- PainShield: A wearable ultrasound therapy device delivering localized energy to relieve pain and promote soft tissue healing for nerve and soft tissue damage, muscle spasms, and joint contractures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NanoVibronix
Sky Medical Technology
HQ: United Kingdom
Website
- Description: Provider of bioelectronic medicine for vascular-related conditions, offering the geko wearable device powered by OnPulse neuromodulation to stimulate the common peroneal nerve and activate calf and foot muscle pumps, increasing venous, arterial, and microvascular circulation to prevent and treat DVT, post-operative edema, and promote wound healing; includes a Partner-With-Us program for clinician collaboration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sky Medical Technology company profile →
Cytogel Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical pain treatments with reduced side effects, including CYT-1010, a novel pain relief drug entering Phase 2 clinical development demonstrating reduced addiction potential and less risk of respiratory depression; endomorphins, a new class for pain management showing potential for safer, more effective options; and patented biocompatible polymer hydrogels for improved drug delivery and medical device coatings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytogel Pharma company profile →
Theralase
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies including Anti-Cancer Therapy (ACT) using light-activated photo dynamic compounds to destroy cancer cells; Cool Laser Therapy (CLT) for knee pain relief by reducing inflammation and accelerating healing; a Phase II NMIBC clinical study of TLD-1433; and Rutherrin, an intravenous combination of TLD-1433 with transferrin to target and destroy cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theralase company profile →
CoLucid
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting central nervous system disorders, developing COL-144, a neurally acting anti-migraine agent for treating migraine, and COL-204, a conjugated stigmine platform producing novel chemical entities for therapy of sleep/wake disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoLucid company profile →
NeurAxis
HQ: United States
Website
- Description: Provider of neuromodulation therapies to address chronic and debilitating conditions in children.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeurAxis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NanoVibronix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NanoVibronix
2.2 - Growth funds investing in similar companies to NanoVibronix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NanoVibronix
4.2 - Public trading comparable groups for NanoVibronix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →